16.02.2021 • NewsMerck

Germany's Merck Invests €18 million in Arizona Site

Germany’s Merck is investing €18 million at its new site in Tempe, Arizona, USA, including the purchase of the 28,000 m2 production facility leased by previous owner Versum Materials, a business it acquired In 2019.

Owning the plant demonstrates its “clear commitment to the site,” the German group said, giving it the flexibility to invest in its production facilities and strengthen R&D capabilities in its global network of high-tech locations.

Jeff White, president of EMD Performance Materials, as Merck’s US-based Performance Materials business is called, said the reasonable purchase price allows more long-term planning for future R&D and production investments, further strengthening the business’s position in the electronics market.

As part of the transaction, Merck has also acquired the ground leasehold interest in the facility. The site within the Arizona State University Research Park employs more than 180 people supporting the group’s Semiconductor Solutions business in the areas of manufacturing, R&D, administration, sales and marketing. In recent years, Versum had invested $10 million to enhance its manufacturing and R&D capabilities. 

Author: Dede Williams, Freelance Journalist

Germany’s Merck is investing €18 million at its site in Tempe, Arizona,...
Germany’s Merck is investing €18 million at its site in Tempe, Arizona, USA, including buying the production facility leased by previous owner Versum Materials, which it acquired In 2019. Owning the plant demonstrates its “clear commitment to the site,” the Darmstadt group said. (c) Merck Group

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.